AI assistant
Verona Pharma plc — Director's Dealing 2022
May 4, 2022
30667_dirs_2022-05-03_098a7a1e-8e12-40bf-9ee4-af13ad79b9e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-05-01
Reporting Person: Rickard Kathleen A. (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-01 | Ordinary Shares | F | 56432 | $0.5225 | Disposed | 2489976 | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units.
F3: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on April 29, 2022 divided by eight (8).
F4: Consists of (i) 1,725,272 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 215,659 ADSs); and (ii) 764,704 Ordinary Shares underlying 95,588 ADSs.